GENELUX CORPORATION
Performance History
| Key Stats | |
|---|---|
| Open | $10.68 |
| Prev. Close | $10.46 |
| EPS | -1.06 |
| Dividend | $0.00 |
| Next Earnings Date | Aug 14, 2023 |
| Dividend Yield % | - |
| Market Cap | $312.59M |
| PE Ratio | - |
| low | high | |
|---|---|---|
| Day Range | 10.57 | 12.25 |
| 52 Week Range | 0.00 | 40.98 |
| Ratios | |
|---|---|
| P/B Ratio | 0.00 |
| Revenue | - |
| Operating M. % | -8,511.76% |
| Earnings | -$25.02M |
| Earnings Growth % | -100.00% |
| EBITDA Margin % | - |
| ROE % | 0.00% |
| EPS | -1.06 |
Score Breakdown
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
| GNLX | Market | |
|---|---|---|
| Value | 53 | 42 |
| Quality | 47 | 46 |
| Ownership | 41 | 39 |
| Growth | 77 | 44 |
| Dividends | - | 32 |
All Score (64 / 100) is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.
Financial Forecast
AI Price Prediction
Analyst Ratings
Correlated Companies
About GENELUX CORPORATION (GNLX)
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1, an animal health product candidate. It has a licensing agreement with ELIAS Animal Health, LLC. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
- ISN
- -
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mr. Thomas Zindrick J.D.
- Headquarters
- Westlake Village
- Employees
- 20
Keep an eye on GENELUX CORPORATION
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
News
Sign up for our newsletter
Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.